Literature DB >> 9700630

Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.

J Odeberg1, Z Yun, A Sönnerborg, O Weiland, J Lundeberg.   

Abstract

The putative interferon sensitivity determining region (ISDR) in the NS5a region of the hepatitis C virus (HCV) was analyzed in 13 interferon alpha (IFN-alpha) treated patients representing genotypes 1a, 1b, and 2b. These patients had previously been followed longitudinally during treatment with respect to viral load and to virus heterogeneity using the hypervariable region 1 (HVR1) sequence as a marker. In the present study, the NS5a region was analyzed for nonresponders and sustained responders using direct DNA sequencing. While the previous results of analyzing viral composition and load showed evidence of selection, no corresponding selection of specific NS5a ISDR sequences was observed in the nonresponders, and identical ISDR sequences were observed among both sustained responders and nonresponders. Thus, we cannot verify a correlation between ISDR sequence and the observed selection of IFN-alpha-resistant quasispecies demonstrated as a restriction of HVR1 heterogeneity. This indicates that the potential for using ISDR as a diagnostic or prognostic marker during IFN-alpha treatment is limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700630     DOI: 10.1002/(sici)1096-9071(199809)56:1<33::aid-jmv6>3.0.co;2-o

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 3.  Clinical significance of hepatitis C virus genotypes.

Authors:  N N Zein
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

4.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 5.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

Review 6.  Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.

Authors:  Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

7.  Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.

Authors:  Melissa D Murphy; Hugo R Rosen; Gail I Marousek; Sunwen Chou
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

8.  Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.

Authors:  Erik Alestig; Birgitta Arnholm; Anders Eilard; Martin Lagging; Staffan Nilsson; Gunnar Norkrans; Thomas Wahlberg; Rune Wejstål; Johan Westin; Magnus Lindh
Journal:  BMC Infect Dis       Date:  2011-05-12       Impact factor: 3.090

9.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.